Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458161 | 0.87 | RXFP1 (0.61) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL26225379 | 0.86 | RXFP1 (0.69) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL3420571 | 0.86 | RAB9A (0.74) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL4426477 | 0.86 | RAB9A (0.73) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL2244769 | 0.85 | NPC1 (0.77) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL3226706 | 0.85 | NPC1 (0.79) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL26225423 | 0.85 | RXFP1 (0.65) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL3219219 | 0.83 | MAPT (0.78) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL24457941 | 0.81 | RXFP1 (0.59) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL24458002 | 0.81 | NPC1 (0.59) | RXFP1MAPTTP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438176-A | 2-phenylbenzotriazol-5-amine derivatives for the treatment and prevention of Hepatitis B Virus (HBV) infection | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | claimed |
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116438176-A | 2-phenylbenzotriazol-5-amine derivatives for the treatment and prevention of Hepatitis B Virus (HBV) infection | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022106588-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| CN-101420952-A | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | RXFP1 401/4885MAPT 4772/4885TP53 4078/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | RXFP1 1398/4885MAPT 2870/4885TP53 4863/4885 |
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HAVCR2, NR1H4, SLC10A1 | RXFP1 2379/4885MAPT 2173/4885TP53 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.